Q2 2025 Management View CEO Robert Barrow highlighted that MindMed remains "on track with enrollment with our three pivotal Phase III trials for our lead asset, MM120 ODT, which is being evaluated in ...

I consulted makeup artists on their favorite techniques and go-to brow products for creating shape, definition and volume in even the sparsest of eyebrows.